Weight change during pharmacological blockade of interleukin-6 or tumor necrosis factor-α in patients with inflammatory rheumatic disorders: A 16-week comparative study

Cytokine

Volumn 61, Issue 2, 2013, Pages 353-355

  Younis, Said ^a   Rosner, Itzhak ^a,b   Rimar, Doron ^a,b   Boulman, Nina ^a,b   Rozenbaum, Michael ^a,b   Odeh, Majed ^a,b   Slobodin, Gleb ^a,b  

^a BNAI ZION MEDICAL CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Infliximab; Tocilizumab; Weight gain

Indexed keywords

INFLIXIMAB; INTERLEUKIN 6; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; HYPERLIPIDEMIA; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPONDYLARTHRITIS; TREATMENT DURATION; WEIGHT CHANGE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BODY MASS INDEX; HUMANS; INFLAMMATION; INTERLEUKIN-6; MICE; MIDDLE AGED; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; WEIGHT GAIN;

MUS;

EID: 84873180906     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.11.007     Document Type: Article

References (10)

1. Tanaka T., Ogata A., Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010, 6:843-854.
2. Kremer J.M., Blanco R., Brzosko M., Burgos-Vargas R., Halland A.M., Vernon E., et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 2011, 63:609-621.
3. Bannwarth B., Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011, 10:123-131.
4. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., et al. Interleukin-6-defficient mice develop mature-onset obesity. Nat Med 2002, 8:75-79.
5. Keller H.H., Ostbye T. Body mass index (BMI), BMI change and mortality in community-dwelling seniors without dementia. J Nutr Health Aging 2005, 9:316-320.
6. Brown R.A., Spina D., Butt S., Summers G.D. Long-term effects of anti-tumor necrosis factor therapy on weight in patients with rheumatoid arthritis. Clin Rheumatol 2012, 31:455-461.
7. Febbraio M.A., Rose-John S., Pedersen B.K. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases?. Clin Pharmacol Ther 2010, 87:396-398.
8. Jansson J.O., Wallenius K., Wernstedt I., Ohlsson C., Dickson S.L., Wallenius V. On the site and mechanism of action of the anti-obesity effects of interleukin-6. Growth Horm IGF Res 2003, 13(Suppl. A):S28-S32.
9. Wernstedt I., Olsson B., Jernas M., Paglialunga S., Carlsson L.M., Smith U., et al. Increased levels of acylation-stimulating protein in interleukin-6 deficient (IL6(-/-)) mice. Endocrinology 2006, 147:2690-2695.
10. Lampson L.A. Monoclonal antibodies in neuro-oncology. Getting past the blood-brain barrier. MABs 2011, 3:153-160.